R-enantiomer of lansoprazole — proton pump inhibitor with delayed dual-release formulation (peaks at 1–2h and 4–5h) that extends acid suppression vs once-released PPIs. Approved for GERD + erosive esophagitis. CYP2C19 substrate.
Half-Life (t½)
PO: 1.7h
Dosing Guidelines
PO: Typical 60 mg (Range: 30–60 mg)
Target Organ Systems
digestive
Pathways It Modulates
Gastric acid secretion (inhibitor) — H+/K+-ATPase (R-enantiomer with dual-release coating)